SCHEMBL4026883

SCHEMBL4026883

CCCn1nc2c(Cl)cccc2c1-c1ccc(OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.44
NR1H2 P55055 9/20 0.42
NR1H3 Q13133 9/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GPR139 Q6DWJ6 1/20 0.40
MAOB P27338 1/20 0.40
GRIK2 Q13002 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GRM2 Q14416 1/20 0.39
NR1I2 O75469 1/20 0.39
NR3C1 P04150 1/20 0.39
AR P10275 1/20 0.39
RXRA P19793 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4034794 0.92 MPO (0.49) ESR1NR1H2NR1H3GPR139MAOB
SCHEMBL4029516 0.86 TNKS (0.46) ESR1NR1H2NR1H3KDM4EALDH1A1
SCHEMBL4200871 0.85 NR1H2 (0.43) NR1H2NR1H3KDM4EALDH1A1GAA
SCHEMBL4031615 0.85 ESR1 (0.62) ESR1NR1H2NR1H3NR1I2NR3C1
SCHEMBL4033022 0.83 ACACA (0.45) NR1H2NR1H3KDM4EALDH1A1GAA
SCHEMBL1407179 0.82 CRHR1 (0.40) ESR1
SCHEMBL4025766 0.78 MPO (0.47) KDM4EALDH1A1GAATSHRLMNA
SCHEMBL4027997 0.78 ESR1 (0.73) ESR1KDM4EALDH1A1NPSR1MEN1
SCHEMBL4031736 0.77 HTR2A (0.45) GPR139MAOBGRIK2MEN1KMT2A
SCHEMBL4025973 0.77 ESR1 (0.59) ESR1NR1H2NR1H3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
EP-1542976-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES Wyeth (US) 2005-06-22 EP disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed
WO-2004031159-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885NR1H2 368/4885NR1H3 417/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 ESR1 2487/4885NR1H2 279/4885NR1H3 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.